tiprankstipranks
Advertisement
Advertisement

DCTH Stock Latest News

Delcath Systems price target raised to $17 from $16 at BTIG
The FlyDelcath Systems price target raised to $17 from $16 at BTIG
10d ago
DCTH
Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer
PremiumThe Fly
Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer
14d ago
DCTH
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress
PremiumThe Fly
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress
2M ago
DCTH
Delcath Shareholders Approve Expanded Equity Plan and Governance
PremiumCompany Announcements
Delcath Shareholders Approve Expanded Equity Plan and Governance
2M ago
8K
DCTH
Delcath Systems Balances Growth with Rising Costs
PremiumCompany Announcements
Delcath Systems Balances Growth with Rising Costs
3M ago
DCTH
Delcath Systems presents new data on M-PHP at ESMO
PremiumThe FlyDelcath Systems presents new data on M-PHP at ESMO
3M ago
DCTH
Delcath Systems reports Q1 EPS (3c), consensus (9c)
Premium
The Fly
Delcath Systems reports Q1 EPS (3c), consensus (9c)
3M ago
DCTH
Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M
Premium
The Fly
Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M
3M ago
DCTH
DCTH Earnings this Week: How Will it Perform?
PremiumPre-Earnings
DCTH Earnings this Week: How Will it Perform?
3M ago
DCTH
Delcath announces Chemosat Hepatic system recommended for liver treatment
PremiumThe Fly
Delcath announces Chemosat Hepatic system recommended for liver treatment
4M ago
DCTH
Delcath Systems management to meet with Craig Hallum
PremiumThe Fly
Delcath Systems management to meet with Craig Hallum
4M ago
DCTH
Delcath Systems Charts Profitable Path Amid Heavy Investment
PremiumCompany Announcements
Delcath Systems Charts Profitable Path Amid Heavy Investment
4M ago
DCTH
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma
PremiumCompany AnnouncementsDelcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma
5M ago
8K
DCTH
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology
Premium
The Fly
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology
5M ago
DCTH
Delcath Systems: Procedure-Driven Growth, Pricing Power, and CHOPIN Trial Catalysts Support Buy Rating
Premium
Ratings
Delcath Systems: Procedure-Driven Growth, Pricing Power, and CHOPIN Trial Catalysts Support Buy Rating
5M ago
DCTH
Delcath Systems price target lowered to $27 from $29 at Clear Street
PremiumThe Fly
Delcath Systems price target lowered to $27 from $29 at Clear Street
5M ago
DCTH
Delcath Systems reports Q4 EPS (5c), consensus (3c)
PremiumThe Fly
Delcath Systems reports Q4 EPS (5c), consensus (3c)
5M ago
DCTH
Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M
PremiumThe Fly
Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M
5M ago
DCTH
Is DCTH a Buy, Before Earnings?
PremiumPre-Earnings
Is DCTH a Buy, Before Earnings?
5M ago
DCTH
Delcath Systems Reports Strong Preliminary 2025 Results
PremiumCompany AnnouncementsDelcath Systems Reports Strong Preliminary 2025 Results
6M ago
8K
DCTH
Delcath Systems: Strong Hepzato Momentum and Center Expansion Drive Buy Rating and $30 Target Despite Execution and Clinical Risks
Premium
Ratings
Delcath Systems: Strong Hepzato Momentum and Center Expansion Drive Buy Rating and $30 Target Despite Execution and Clinical Risks
7M ago
DCTH
Delcath Systems price target raised to $29 from $28 at Clear Street
Premium
The Fly
Delcath Systems price target raised to $29 from $28 at Clear Street
7M ago
DCTH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >